Diebold Nixdorf: Index Inclusion Is Additional Validation Of Diebold Nixdorf's Turnaround

Diebold Nixdorf remains a Buy as operational momentum, profitability, and free cash flow continue to strengthen, with FY 2026 guidance improving. DBD's addition to the S&P SmallCap 600 has driven near-term buying pressure, but the fundamental investment case is underpinned by rising EPS and margin expansion. Revenue for FY 2025 grew 1.5% to $3.80 billion, EBITDA margin improved to 12.7%, and free cash flow surged 120%, with a robust $300 million in buyback authorizations last year.